| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AIM ImmunoTech Inc. | Ampligen (AMP-270) | Pancreatic cancer | Phase 2 | Trial Planned | Intravenous | Oncology |
| AIM ImmunoTech Inc. | IP Ampligen (rintatolimod) and interferon-alpha (IFNα) | Cisplatin resistant advanced recurrent ovarian cancer | Phase 2 | Data Released | intraperitoneal | Oncology |
| AIM ImmunoTech Inc. | Ampligen and celecoxib | Primary PD-1/PD-L1 resistant melanoma | Phase 2 | Trial Planned | Ampligen intravenous Celecoxib oral | Oncology |
| AIM ImmunoTech Inc. | Ampligen, Intron A | Prostate Cancer | Phase 2 | Ampligen intravenous Intron A subcutaneous or intramuscular | Oncology | |
| AIM ImmunoTech Inc. | Ampligen (AMP-511) | Post-COVID-19 conditions | Phase 2 | Ongoing | Intravenous | COVID-19 |
| AIM ImmunoTech Inc. | Ampligen (AMP-518) | Post-COVID conditions | Phase 2 | Data Released | Intravenous | N/A |
| AIM ImmunoTech Inc. | Ampligen, Intron A, and celecoxib | Colorectal cancer | Phase 2 | Ampligen intravenous Intron A subcutaneous intramuscular intravenous celecoxib oral | Oncology | |
| Ainos Inc. | VELDONA | Sjögren's syndrome | Phase 3 | Ongoing | oral | Immunology |